New drug shows promise in cutting heavy drinking days

NCT ID NCT06987513

Completed Disease control Sponsor: Altimmune, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tests a weekly injection called pemvidutide to see if it can reduce heavy drinking in adults with alcohol use disorder who are also overweight or obese. About 100 participants will receive either the drug or a placebo for 24 weeks. The main goal is to measure the change in the number of heavy drinking days per week.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER (AUD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse Obesity Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER (AUD)

Contacts and locations

Locations

Altimmune Clinical Study Site

Aurora, Colorado, 80045, United States
Altimmune Clinical Study Site

New Haven, Connecticut, 06511, United States
Altimmune Clinical Study Site

Fort Myers, Florida, 33912, United States
Altimmune Clinical Study Site

University Park, Florida, 34201, United States
Altimmune Clinical Study Site

North Canton, Ohio, 44720, United States
Altimmune Clinical Study Site

Tulsa, Oklahoma, 74136, United States
Altimmune Clinical Study Site

Philadelphia, Pennsylvania, 19104, United States
Altimmune Clinical Study Site

Providence, Rhode Island, 02923, United States
Altimmune Clinical Study Site

Charleston, South Carolina, 29425, United States
Altimmune Clinical Study Site

Charlottesville, Virginia, 22903, United States
Altimmune Clinical Study Site

Richmond, Virginia, 23298, United States
Altimmune Clinical Study Site

Los Angeles, California, 90038, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.